I don't necessarily agree with you on this. There are many other factors/events that could/should happen between now and mid/late November....all of which will add value from where we're currently at. Vyvanse possibly having a 3 month delay isn't that big of a deal if it's accompanied by a drug launch or two, positive BE study/studies being reported, a new filing of a needle mover, and/or another drug approval. Multiple irons in the fire=cooking either way. Just a matter of whether it's a slow simmer, or a flash fry. Either we we're all gonna end up being well fed. JMHO